Immunogenicity of the Tuberculosis Vaccine MVA85A Is Reduced by Coadministration with EPI Vaccines in a Randomized Controlled Trial in Gambian Infants
New tuberculosis vaccines are urgently needed to curtail the current epidemic. MVA85A is a subunit vaccine that could enhance immunity from BCG vaccination. To determine MVA85A safety and immunogenicity as well as interactions with other routine vaccines administered in infancy, we randomized health...
Príomhchruthaitheoirí: | Ota, M, Odutola, A, Owiafe, P, Donkor, S, Owolabi, O, Brittain, N, Williams, N, Rowland-Jones, S, Hill, A, Adegbola, R, Mcshane, H |
---|---|
Formáid: | Journal article |
Teanga: | English |
Foilsithe / Cruthaithe: |
2011
|
Míreanna comhchosúla
Míreanna comhchosúla
-
Immunogenicity of the tuberculosis vaccine MVA85A is reduced by coadministration with EPI vaccines in a randomized controlled trial in Gambian infants.
de réir: Ota, M, et al.
Foilsithe / Cruthaithe: (2011) -
A new TB vaccine, MVA85A, induces durable antigen-specific responses 14 months after vaccination in African infants
de réir: Odutola, A, et al.
Foilsithe / Cruthaithe: (2012) -
A new TB vaccine, MVA85A, induces durable antigen-specific responses 14 months after vaccination in African infants.
de réir: Odutola, A, et al.
Foilsithe / Cruthaithe: (2012) -
Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa.
de réir: Brookes, R, et al.
Foilsithe / Cruthaithe: (2008) -
Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa.
de réir: Roger H Brookes, et al.
Foilsithe / Cruthaithe: (2008-08-01)